uniQure Granted US Patent to Use FIX-Padua for Hemophilia B Gene Therapy
The U.S. Patent and Trademark Office has granted uniQure a third patent covering the formulation and use of the…
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
The U.S. Patent and Trademark Office has granted uniQure a third patent covering the formulation and use of the…
A natural anticoagulant protein called tissue factor pathway inhibitor (TFPI) is critical for defining the bleeding severity profiles of…
Many hemophilia patients experience undiagnosed symptoms of depression and anxiety that can impact their ability to cope with the disease…
Mitsubishi Tanabe Pharma is joining forces with researchers from Jichi Medical University to…
The National Hemophilia Foundation (NHF) and Hemophilia Federation of America (HFA) asked Bayer to clarify the risks to…
Investigational gene therapy SB-525 can safely induce durable clotting factor VIII (FVIII) activity in patients with severe hemophilia…
Self-reported health outcomes of hemophilia patients provide useful and clinically valuable data on the efficacy of treatments, a population-based study…
For the second year, key pharmaceutical and academic leaders in hemophilia therapy development will gather at the Hemophilia Drug Development Summit…
More than half of people with hemophilia in Japan fail to take part in sports or other physical activities at…
Two new mutations affecting the production of functional clotting factor VIII were identified in a group of Vietnamese patients with…
Get regular updates to your inbox.